<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02497157</url>
  </required_header>
  <id_info>
    <org_study_id>TRICC1414</org_study_id>
    <secondary_id>UMIN000017102</secondary_id>
    <nct_id>NCT02497157</nct_id>
  </id_info>
  <brief_title>Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer</brief_title>
  <acronym>BeTRI</acronym>
  <official_title>Phase II Trial of FOLFOXIRI + Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hiroshima Prefectural Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Hospital Organization Shikoku Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of fluorouracil (5-FU),
      levofolinate calcium (l-LV), oxaliplatin (L-OHP) and irinotecan hydrochloride hydrate
      (CPT-11) (FOLFOXIRI) plus bevacizumab in untreated metastatic colorectal cancer patients who
      harbor Uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) *1/*1, *1/*6 or
      *1/*28.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 21, 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (RR) by response evaluation criteria in solid tumors (RECIST v1.1)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>RR will be calculated as the ratio of the number of eligible patients who experienced a confirmed Complete response(CR) or Partial response(PR) by RECIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>TTF is defined as the time from date of starting treatment until date of treatment discontinuation, the first documented progression or death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>PFS is defined as the time from date of starting treatment until date of the first documented progression or death from any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>OS is defined as the time from date of starting treatment until date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>R0 resection rate will be calculated as the ratio of the number of eligible patients who experienced a complete (R0) resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative dose intensity (RDI)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>RDI will be calculated as the ratio of actual delivered dose intensity in comparison with planned dose intensity. Dose intensity (DI) is defined as the amount of drug delivered per unit time, expressed in mg/m2/week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Early tumor shrinkage (ETS) rates in 8 weeks after starting the treatment, evaluated by RECIST v1.1</measure>
    <time_frame>Baseline (week 0), week 8</time_frame>
    <description>ETS will be calculated as the ratio of the number of eligible patients who experienced a 20% or more tumor shrinkage at week 8 compared with baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Deepness of response (DoR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>DoR will be calculated as the median of the maximum tumor shrinkage rates.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FOLFOXIRI plus bevacizumab [oxaliplatin (L-OHP): 85 mg/sq.m., irinotecan hydrochloride hydrate (CPT-11): 165 mg/sq.m., continuous intravenous infusion of fluorouracil (CIV 5-FU): 3,200 mg/sq.m., Levofolinate calcium (l-LV): 200 mg/sq.m., bevacizumab: 5 mg/kg]. The treatment will be repeated every 2 weeks, for up to 12 cycles, unless the disease progression, unacceptable toxicity, tumor resection or consent withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin (L-OHP)</intervention_name>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan hydrochloride hydrate (CPT-11)</intervention_name>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous intravenous infusion of fluorouracil (CIV 5-FU)</intervention_name>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofolinate calcium (l-LV)</intervention_name>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab (Bmab)</intervention_name>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed adenocarcinoma of the colon or rectum.

          2. Unresectable or recurrent colorectal cancer patient.

          3. One or more measurable lesion in RECIST ver.1.1 criteria.

          4. No prior chemotherapy, immunotherapy, and radiotherapy.

          5. Life expectancy at least 3 months.

          6. Patients who harbor UGT1A1*1/*1, *1/*6 or *1/*28.

          7. The Eastern Cooperative Oncology Group (ECOG) performance status of =&lt;1.

          8. Vital organ functions (listed below) are preserved within 14 days prior to entry.

             White blood cell count (WBC): &gt;= 3,000 per cubic millimeter Neu: &gt;= 1,500 per cubic
             millimeter Platelet count (PLT): &gt;= 100,000 per cubic millimeter Aspartate
             aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT): &lt;= 100 IU/L, &lt;= 150
             IU/L in cases with liver metastasis T-bil: &lt;= 1.5 mg/dL Serum creatinine: &lt;= 1.50
             mg/dL Proteinuria: &lt;= 1+ Prothrombin time-international normalized ratio (PT-INR): &lt;
             1.5

          9. Written informed consent.

        Exclusion Criteria:

          1. Vermiform appendix cancer and anal canal cancer.

          2. Administration of blood products/ granulocyte-colony stimulating factor (G-CSF), and
             blood transfusion within 14 days prior to enrollment.

          3. Synchronous multiple malignancy or metachronous multiple malignancy less than 5 years
             disease free interval.

          4. Hepatitis B virus antigen (HBs-Ag)(+), or hepatitis C virus antibody (HCV-Ab)(+).

          5. History of severe allergy.

          6. Sensory alteration or paresthesia interfering with function.

          7. Prior radiotherapy for ilium and abdomen.

          8. Infectious disease.

          9. Uncontrolled diarrhea.

         10. Ileus or bowel obstruction.

         11. Interstitial lung disease or pulmonary fibrosis.

         12. Malignant coelomic fluid required drainage.

         13. Administration of atazanavir sulfate.

         14. Heart disease to be clinically problem.

         15. Major surgical procedure or intestinal resection within 28 days prior to enrollment or
             colostomy within 14 days prior to enrollment.

         16. Known brain metastasis or strongly suspected of brain metastasis.

         17. History of a thromboembolic disease.

         18. Receiving anti-platelet drugs.

         19. Poorly controlled gastrointestinal ulcer.

         20. History of intestinal perforation within the past 12 months.

         21. Poorly controlled hypertension.

         22. Poorly controlled diabetes mellitus.

         23. Severe mental disorders.

         24. Women who are pregnant or nursing, men and women who wish to conceive a child or with
             no intention to contraception.

         25. Any other cases who are regarded as inadequate for study enrollment by investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsunori Shinozaki, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hiroshima Prefectural Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomohiro Nishina, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital Organization Shikoku Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Matsuyama Red Cross Hospital</name>
      <address>
        <city>Matsuyama-city</city>
        <state>Ehime-prefecture</state>
        <zip>790-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital</name>
      <address>
        <city>Kita-gun, Miki-cho</city>
        <state>Kagawa-prefecture</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawasaki Medical School Hospital</name>
      <address>
        <city>Kurashiki-city</city>
        <state>Okayama-prefecture</state>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai General Hospital</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama-prefecture</state>
        <zip>700-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama-prefecture</state>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Rosai Hospital</name>
      <address>
        <city>Okayama-city</city>
        <state>Okayama-prefecture</state>
        <zip>702-8055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima Red Cross Hospital</name>
      <address>
        <city>Komatsushima-city</city>
        <state>Tokushima-prefecture</state>
        <zip>773-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>irinotecan</keyword>
  <keyword>hydrochloride hydrate</keyword>
  <keyword>fluorouracil</keyword>
  <keyword>levofolinate calcium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

